Revelation Biosciences (NASDAQ:REVB) Issues Quarterly Earnings Results

Revelation Biosciences (NASDAQ:REVB) released its earnings results on Friday. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.01, FiscalAI reports.

Revelation Biosciences Price Performance

NASDAQ:REVB traded up $0.02 during midday trading on Friday, reaching $1.14. 25,572 shares of the company traded hands, compared to its average volume of 42,163. Revelation Biosciences has a twelve month low of $0.88 and a twelve month high of $11.72. The firm has a market capitalization of $4.46 million, a price-to-earnings ratio of -0.09 and a beta of -0.15. The company has a fifty day moving average price of $1.04 and a 200 day moving average price of $1.27.

Institutional Investors Weigh In On Revelation Biosciences

An institutional investor recently raised its position in Revelation Biosciences stock. Armistice Capital LLC grew its position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 434,272 shares of the company’s stock after acquiring an additional 354,272 shares during the quarter. Armistice Capital LLC owned about 6.29% of Revelation Biosciences worth $347,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.